We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

The Prevention Options for Women Evaluation Research (POWER) Cohort

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03490058
Recruitment Status : Completed
First Posted : April 6, 2018
Last Update Posted : December 6, 2021
Desmond Tutu HIV Foundation
Wits Reproductive Health and HIV Institute
Kenya Medical Research Institute
United States Agency for International Development (USAID)
RTI International
Harvard Medical School (HMS and HSDM)
University of Pittsburgh
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Connie Celum, University of Washington

Brief Summary:
The POWER Cohort study is a PrEP implementation project to demonstrate Pre-exposure prophylaxis (PrEP) delivery for young women in Cape Town and Johannesburg, South Africa and Kisumu, Kenya.

Condition or disease Intervention/treatment
HIV/AIDS Drug: Truvada

Detailed Description:
PrEP will be delivered to young women according to emerging national guidelines in family planning clinics (Kisumu, Kenya), youth friendly clinics (Johannesburg, South Africa), and mobile youth friendly clinics (Cape Town, South Africa). The investigators will evaluate PrEP delivery and follow cohorts of young women at each clinic location to understand PrEP uptake and use. In the Kisumu clinics, the investigators will also offer expedited partner therapy and partner HIV self-tests to women who test positive for chlamydia and/or gonorrhea. At one clinic in Johannesburg, the investigators will evaluate the use of a decision support tool to improve the decision to initiate PrEP.

Layout table for study information
Study Type : Observational
Actual Enrollment : 2255 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Cohort for Evaluation of Open-label PrEP Delivery Among Kenyan and South African Women: The POWER Cohort
Actual Study Start Date : June 14, 2017
Actual Primary Completion Date : December 4, 2020
Actual Study Completion Date : July 23, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS
Drug Information available for: Truvada

Group/Cohort Intervention/treatment
Young women
Sexually active HIV-uninfected women between 16-25 years of age will be given Truvada.
Drug: Truvada
A fixed dose of oral co-formulated tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) will be used as PrEP.

Primary Outcome Measures :
  1. Demonstrate PrEP delivery models for young women in different settings and geographies. [ Time Frame: Up to 36 months ]
    Mixed methods assessment of how PrEP is implemented at the user, provider, health care facility, and community levels.

Secondary Outcome Measures :
  1. PrEP initiation [ Time Frame: Up to 36 months ]
    Measure the number of young women who initiate PrEP.

  2. PrEP adherence [ Time Frame: Up to 36 months ]
    Adherence by young women to PrEP. Adherence will be measured by the timing of PrEP refills and self-reported PrEP use. Blood samples for detection and quantification of PrEP levels (testing in batch) will be done for those who seroconvert to HIV and a subset who remain HIV uninfected.

  3. HIV seroconversion [ Time Frame: Up to 36 months ]
    Assess HIV incidence during PrEP use and non-use.

Other Outcome Measures:
  1. Assess cost and cost-effectiveness of PrEP when delivered in public health clinics. [ Time Frame: Up to 36 months ]
    Time-motion studies will be conducted to define the cost and cost effectiveness of the intervention in terms of HIV infections averted, disability-adjusted life years saved, and incremental cost-effectiveness of PrEP over routine HIV care.

  2. Evaluate the acceptability of delivering expedited partner therapy. [ Time Frame: Up to 36 months ]
    Measure the number of women who accept STI expedited partner therapy and HIV self-test kits for their partners.

  3. Assess the effect of a decision support tool on PrEP uptake [ Time Frame: Up to 36 months ]
    Using a randomized design, evaluate if a decision support tool increases PrEP uptake.

  4. Evaluate the impact of HIV self-testing on PrEP delivery among young women receiving PrEP [ Time Frame: Up to 12 months ]
    Using a pretest posttest design, evaluate the feasibility of integrating HIV self-testing into PrEP delivery.

Biospecimen Retention:   Samples Without DNA
Dried blood spots

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years to 25 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Sexually active HIV uninfected women ages 16-25 will be recruited from family planning clinics, youth clinics, and youth outreach programs.

Inclusion Criteria:

  • Age 16-25 (16 and 17 year olds, where permissible by national regulations and local IRB approval)
  • Able and willing to provide written informed consent
  • Recently sexually active (defined as having had vaginal intercourse at least once in the previous three months)
  • HIV uninfected based on negative HIV rapid tests, on the date of enrollment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03490058

Layout table for location information
Kenya Medical Research Institute
Kisumu, Kenya
South Africa
Desmond Tutu HIV Foundation
Cape Town, South Africa
Wits Reproductive Health and HIV Institute
Johannesburg, South Africa
Sponsors and Collaborators
University of Washington
Desmond Tutu HIV Foundation
Wits Reproductive Health and HIV Institute
Kenya Medical Research Institute
United States Agency for International Development (USAID)
RTI International
Harvard Medical School (HMS and HSDM)
University of Pittsburgh
National Institute of Mental Health (NIMH)
Layout table for investigator information
Principal Investigator: Connie L Celum, MD, MPH University of Washington
Principal Investigator: Jared M Baeten, MD, PhD University of Washington
Study Director: Rachel Johnson, MPH University of Washington
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Connie Celum, Prof of Medicine & Global Health, Adjunct Prof of Epidemiology, SOM: Global Health, University of Washington
ClinicalTrials.gov Identifier: NCT03490058    
Other Study ID Numbers: STUDY00000950
R01MH114544 ( U.S. NIH Grant/Contract )
AID-OAA-A-15-00034 ( Other Grant/Funding Number: US Agency for International Development )
First Posted: April 6, 2018    Key Record Dates
Last Update Posted: December 6, 2021
Last Verified: December 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Data from the POWER Cohort Study will be available at the end of the project by contacting the Principal Investigators.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Connie Celum, University of Washington:
pre-exposure prophylaxis
young women
delivery of health care
HIV infections/prevention
Additional relevant MeSH terms:
Layout table for MeSH terms
Acquired Immunodeficiency Syndrome
HIV Infections
Blood-Borne Infections
Communicable Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Slow Virus Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Anti-HIV Agents
Anti-Retroviral Agents